Coherus terminates TIGIT program collaboration with Junshi Biosciences after portfolio review

Coherus Oncology, Inc.

Delivered notice of termination on January 10, 2024 for the TIGIT Program (CHS-006).
Decision follows Surface Oncology acquisition and portfolio prioritization; agreement remains effective for LOQTORZI (toripalimab-tpzi).
Coherus will continue to support patients in ongoing CHS-006 studies (NCT05061628, NCT05757492).
Company believes termination is in its best interests; wind-down expected over coming months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.